Clinical Trials · NCT05498272
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Rana McKay, MD
- Enrollment
- 32
- Start date
- Feb 2023
- Locations
- 6 sites, United States
- Primary endpoint
- Pathological Complete Response (pCR) rate